Table 3. Association between race, molecular subtype, and clinicopathologic characteristics.
| Variable | African Americans | p-value | Caucasians | p-value | ||
|---|---|---|---|---|---|---|
| Luminal | TNBC | Luminal | TNBC | |||
| 43 (37%) | 73 (63%) | 92 (58%) | 68 (42%) | |||
| Mean age, years (IQR) | 59 (48–74) |
55 (46–65) |
0.160 | 55 (48–63) |
55 (46–65) |
0.796 |
| Tumor Stage | >0.000 | 0.943 | ||||
| early (I & II) | 33 (77%) | 49 (77%) | 66 (72%) | 50 (73.5%) | ||
| late (III & IV) | 10 (23%) | 24 (33%) | 26 (28%) | 18 (26.5%) | ||
| Follow up, mean months (IQR) | 63.8 (33.2–102.2) |
64.9 (20.3–105.7) |
0.891 | 85.0 (57.4–120) |
72.3 (81–120) |
0.053 |
| Event (cause of death) | 0.579 | 0.170 | ||||
| Alive/other | 34 (79%) | 53 (73%) | 77 (84%) | 70 (74%) | ||
| Death from cancer | 9 (21%) | 20 (27%) | 15 (16%) | 18 (27%) | ||
| Grade | >0.000 | >0.000 | ||||
| I &II | 18 (45%) | 8 (11%) | 57 (63%) | 11 (17%) | ||
| III | 22 (55%) | 65 (89%) | 34 (37%) | 55 (83%) | ||
| p53 status | 0.601 | 0.626 | ||||
| Wild-type | 16 (60%) | 49 (67%) | 77 (84%) | 54 (79%) | ||
| Mutated | 17 (40%) | 24 (33%) | 15 (16%) | 14 (21%) | ||
| Codon 72 | 0.077 | 0.003 | ||||
| Arg/Arg | 10 (23%) | 19 (26%) | 40 (44%) | 48 (71%) | ||
| Arg/Pro | 16 (40%) | 15 (21%) | 21 (23%) | 9 (13%) | ||
| Pro/Pro | 17 (37%) | 39 (53%) | 31 (33%) | 11 (16%) | ||
| Interaction p53*SNP | 0.451 | 0.167 | ||||
| Wild-type p53 (all SNPs) | 26 (60%) | 49 (67%) | 77 (84%) | 54 (79%) | ||
| Arg/Arg & p53 mut | 3 (7%) | 4 (6%) | 6 (7%) | 11 (16%) | ||
| Arg/Pro & p53 mut | 5 (12%) | 3 (4%) | 5 (5%) | 1 (2%) | ||
| Pro/Pro & p53 mut | 9 (21%) | 17 (23%) | 4 (4%) | 2 (3%) | ||
Abbreviations: TNBC, triple-negative molecular subtype, n, total number of participants per group, IQR = interquartile range, mut = mutated